Journal
FUTURE ONCOLOGY
Volume 6, Issue 5, Pages 811-821Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/FON.10.34
Keywords
apoptosis; cancer therapy; CASMER; death receptor; death-inducing signaling; complex; edelfosine ether phospholipids; Fas/CD95 lipid raft; mechanism of action
Categories
Funding
- Ministerio de Ciencia e Innovacion [SAF2005-04293, SAF2008-02251, RD06/0020/1037]
- Red Tematica de Investigacion Cooperation en Cancer, Instituto de Salud Carlos III
- Fondo Europe de Desarrollo Regional of the European Union)
- Fondo de Investigacion Sanitaria - Instituto de Salud Carlos III
- European Commission (FIS-FEDER) [06/0813, PS09/01915]
- Junta de Castilla y Leon [2009]
- Ministerio de Ciencia e Innovacion of Spain
Ask authors/readers for more resources
There is an imperative need to overcome the rather poor outcomes of current cancer chemotherapy with further development of novel targets and drugs. Direct activation of the cancer cell apoptotic machinery constitutes an appealing approach. Recent findings have shown that apoptosis can be triggered by co-aggregation of lipid rafts with death receptors and downstream signaling molecules, thus facilitating their interactions to convey apoptotic signals. We postulate this cluster of apoptotic signaling molecule-enriched rafts (CASMER) as a novel supramolecular entity that modulates apoptosis, representing a new target in cancer therapy. The development of drugs that target lipid rafts leading to the formation of clusters of apoptotic signaling molecule-enriched rafts offers new opportunities for therapeutic intervention in cancer therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available